Oncology

Newly published data suggest a Test-and-Treat approach to H. Pylori infection is viable and may carry several health benefits

MicroThermX® Microwave Ablation System cleared for laparoscopic ablation procedures using image guidance

BioLight Life Sciences is to enter a strategic partnership that will significantly advance its prospects in the Chinese market

Code represents important first step In process to gain coverage for incisionless procedures to treat the underlying cause of GERD

Clinical research to be presented at International Breast Cancer Conference confirms how ‘scalp cooling works’

Micromedic Technologies’ CellDetect® non-invasive test for detecting bladder cancer in urine offers potential to supplant cystoscopy for bladder cancer surveillance

Real-time targeting could see high field MRI-guided Radiation Therapy revolutionise cancer therapy

Philips’ new lung screening solution offers health care providers a faster and more definitive pathway to lung cancer detection and treatment.

The use of the Seno Imagio breast imaging system and its associated predictive model appear to have the potential to significantly improve the physicians’ ability to accurately rule out breast cancer compared to traditional ultrasound alone.

Covidien’s updated software features a more intuitive interface that helps reduce planning time and enhances airway visualization.

Study results show that PathFinderTG is the most accurate, clinically validated test available for determining risk of malignancy in pancreatic cysts.

Covidien supports publicity initiative to drive earlier diagnosis of lung cancer, opening up treatment options and improved patient outcomes

Robot-Assisted Radical Prostatectomy has only been around since the turn of the century so this study of ten year survival rates is both rare and encouraging.

Toshiba says its new imaging system offers a package of features that make it the most patient friendly PET/CT system on the market.

Robotically assisted surgery is in the spotlight again as one commentator says it doesn’t justify its cost. Our weekly editorial discusses whether providers have much choice about whether to invest if they’re to remain current and competitive.

A Reuters article tells us that Johnson & Johnson has suspended the sale of its power morcellators until the risk of spreading cancerous cells is better understood. This in response to earlier FDA guidance on the subject.